Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications
- PMID: 32530884
- DOI: 10.1097/ADM.0000000000000676
Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications
Abstract
Objectives: Treatment with medications for opioid use disorder such as buprenorphine improves patient morbidity and mortality as well as treatment adherence, an important component of patient care. Buprenorphine is combined with naloxone to reduce misuse; and, when taken sublingually, naloxone is poorly absorbed. Urine testing for buprenorphine is a common way to monitor adherence. Some patients who want to appear adherent may directly tamper with their urine by adding buprenorphine to their urine to allow for the detection without ingestion. Practitioners may rely upon the concentration of buprenorphine and the metabolite, norbuprenorphine, and utilize the ratio of metabolite to parent compound (norbuprenorphine:buprenorphine - N:B ratio) to discern possible evidence of tampering; however, there remains debate as to what specific ratio may signify this practice. Testing for naloxone may also help determine if urine tampering occurred as only low naloxone concentrations are found in the urine when taken by a sublingual route.
Methods: To determine a reliable N:B ratio that may be used to identify possible urine tampering by adding parent drug directly to urine, we examined 136,605 urine samples for quantitative concentrations of buprenorphine and norbuprenorphine by LC-MS/MS performed at a commercial laboratory. After identifying abnormal ratios (<0.02), we then compared them with naloxone concentrations and specimen validity testing, other markers that may coincide with specimen tampering of this type.
Results: Correlating urinary buprenorphine and norbuprenorphine concentrations, we found 2 distinct patient populations, which could be distinguished by N:B ratios ranging from 0.01 to 0.2. In addition, while the distribution of urine naloxone concentrations itself did not demonstrate distinct populations, naloxone was able to further flag potential tampered specimens when combined with N:B ratios. Abnormal specimen validity testing was additionally found more commonly in cases with N:B ratios <0.02.
Conclusions: This comprehensive study compared N:B ratios with naloxone concentrations and specimen validity testing. This study suggests that a N:B ratio of <0.02 in concert with high naloxone concentrations (>1000 ng/ml) can help to identify potential cases of tampered urine samples.
Similar articles
-
Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples: Can They be Detected When Buprenorphine/Naloxone Film is Dipped into Urine or Water?Subst Use. 2024 Jan 20;18:11782218231223673. doi: 10.1177/11782218231223673. eCollection 2024 Jan-Dec. Subst Use. 2024. PMID: 38433747 Free PMC article.
-
Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.Subst Abuse Rehabil. 2016 Jun 14;7:81-6. doi: 10.2147/SAR.S100998. eCollection 2016. Subst Abuse Rehabil. 2016. PMID: 27366109 Free PMC article. Review.
-
Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.Methods Mol Biol. 2016;1383:69-78. doi: 10.1007/978-1-4939-3252-8_8. Methods Mol Biol. 2016. PMID: 26660175
-
Patterns of free (unconjugated) buprenorphine, norbuprenorphine, and their glucuronides in urine using liquid chromatography-tandem mass spectrometry.J Anal Toxicol. 2012 Mar;36(2):81-7. doi: 10.1093/jat/bkr020. J Anal Toxicol. 2012. PMID: 22337776
-
Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.Clin Pharmacokinet. 2005;44(7):661-80. doi: 10.2165/00003088-200544070-00001. Clin Pharmacokinet. 2005. PMID: 15966752 Review.
Cited by
-
Buprenorphine, Norbuprenorphine, and Naloxone Levels in Adulterated Urine Samples: Can They be Detected When Buprenorphine/Naloxone Film is Dipped into Urine or Water?Subst Use. 2024 Jan 20;18:11782218231223673. doi: 10.1177/11782218231223673. eCollection 2024 Jan-Dec. Subst Use. 2024. PMID: 38433747 Free PMC article.
-
Bridging the gap: The critical role of laboratory developed tests in clinical toxicology.J Mass Spectrom Adv Clin Lab. 2023 Feb 22;28:70-74. doi: 10.1016/j.jmsacl.2023.02.007. eCollection 2023 Apr. J Mass Spectrom Adv Clin Lab. 2023. PMID: 36872953 Free PMC article. Review.
-
Do buprenorphine doses and ratios matter in medication assisted treatment adherence.Ment Health Clin. 2022 Aug 23;12(4):241-246. doi: 10.9740/mhc.2022.08.241. eCollection 2022 Aug. Ment Health Clin. 2022. PMID: 36071736 Free PMC article.
-
Evaluation of adherence monitoring in buprenorphine treatment: A pilot study using timed drug assays to determine accuracy of testing.Br J Clin Pharmacol. 2023 Jul;89(7):1938-1947. doi: 10.1111/bcp.15318. Epub 2022 Mar 31. Br J Clin Pharmacol. 2023. PMID: 35304767 Free PMC article.
-
A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.Addict Sci Clin Pract. 2021 Sep 30;16(1):59. doi: 10.1186/s13722-021-00264-4. Addict Sci Clin Pract. 2021. PMID: 34593036 Free PMC article.
References
-
- Accurso AJ, Lee JD, McNeely J. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. J Subst Abuse Treat 2017; 83:62–67.
-
- Belsey SL, Couchman L, Flanagan RJ. Buprenorphine detection in urine using liquid chromatography–high-resolution mass spectrometry: comparison with cloned enzyme donor immunoassay (ThermoFisher) and homogeneous enzyme immunoassay (immunalysis). J Anal Tox 2014; 38:438–443.
-
- Bottcher M, Beck O. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J Anal Toxicol 2005; 29:769–776.
-
- Cone EJ, Gorodetzky CW, Yousefneiad D, et al. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispo 1984; 12:577–581.
-
- Donroe JH, Holt SR, O’Conner PG, et al. Interpreting quantitative urine buprenorphine and norbuprenorphine levels in office-based clinical practice. Drug Alcohol Depend 2017; 180:46–51.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources